NSCLC术后铂类药物辅助化疗疗效与ERCC1和P53蛋白表达的分析

目的回顾性的分析ERCC1和P53的表达与非小细胞肺癌(NSCLC)患者术后铂类药物化疗疗效的关系。方法免疫组化法检测53例手术切除NSCLC患者石蜡包埋标本中ERCC1和P53蛋白的表达,所有患者接受4～6周期铂类为基础的辅助化疗,分析蛋白表达与患者中位生存时间(MST)和无病生存时间(DFT)的关系。结果①ERCC1和P53的阳性表达率为42.8%和39.6%,与患者的临床特征无关。②单一蛋白阴性组的MST及中位DFT均长于阳性组。③两种蛋白均阴性表达组的MST及中位DFT均长于阳性表达组。结论检测ERCC1和P53蛋白的表达能预测铂类药物化疗疗效。

Correlation between Curative Efficacy of Post-operative Platinum-based Chemotherapy and ERCC1 and P53 Protein Expression in NSCLC: A Retrospective Analysis

Objective To retrospectively analyze the correlation between ERCC1 and P53 protein expression and the curative efficacy of post-operative platinum-based chemotherapy in NSCLC. Methods The expression levels of ERCC1 and P53 in paraffin specimens of 53 cases of resected NSCLC were detected by immunohistochemistry, and all cases were treated by 4 to 6 cycles of platinum-based chemotherapy. The correlation of the protein expression with the median survival time （MST） and the median disease-free time（DFT） was analyzed. Results The positive expression rate of ERCCI was 42.8% and that of P53 was 39.6%, with no significant correlation between their expression and the clinical characteristics. The median survival time and the median disease-free time were significantly longer in ERCC1 positive group than those in ERCC1 negative group, and the median survival time and the median disease-free time were significantly longer in the P53 negative group compared to the P53 positive group. The median survival time and the median disease-free time were significantly longer in ERCC1 and P53 negative groups compared to ERCC1 and P53 positive groups. Conclusion The detection of the ERCC1 and P53 protein expression can predict the curative efficacy of platinum-based chemotherapy in NSCLC.